Trial Profile
Phase II Trial of Cabozantinib (XL184) in Patients With Advanced Solid (Non-breast, Non-prostate) Malignancies and Bony Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2022
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Bone metastases; Sarcoma; Solid tumours
- Focus Biomarker; Therapeutic Use
- 05 Jul 2022 Results published in the Oncologist
- 08 Sep 2020 Status changed from active, no longer recruiting to completed.
- 30 Jul 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.